Skip to main content
. 2020 May 13;20(1):611–622. doi: 10.3892/ol.2020.11618

Figure 6.

Figure 6.

Alterations of IL-17A and IL-35 levels in BALF from patients with CIP and controls. (A and B) IL-17A levels in BALF of (A) patients with CIP and (B) controls. (C and D) IL-35 levels in BALF of (C) patients with CIP and (D) controls. IL, interleukin; CIP, checkpoint inhibitor pneumonitis; BALF, bronchoalveolar lavage fluid; ICI, immune checkpoint inhibitors.